Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
$0.60
$0.60
$0.48
▼
$25.44
$1.23M1.4122,322 shsN/A
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
$0.12
+13.6%
$0.11
$0.03
▼
$0.22
$1.32M1.5227,637 shs32,939 shs
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
$0.02
-8.0%
$0.78
$0.02
▼
$10.99
$363K1.1624.32 million shs121.84 million shs
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
$0.00
$0.07
▼
$6.56
$1.04M1.36315,915 shs220 shs
7 Energy Stocks to Buy and Hold Forever Cover

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
+13.64%-2.71%+11.00%+53.33%+61.97%
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
0.00%-8.05%-95.90%-99.20%-99.72%
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
0.00%0.00%0.00%0.00%+150.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
$0.60
$0.60
$0.48
▼
$25.44
$1.23M1.4122,322 shsN/A
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
$0.12
+13.6%
$0.11
$0.03
▼
$0.22
$1.32M1.5227,637 shs32,939 shs
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
$0.02
-8.0%
$0.78
$0.02
▼
$10.99
$363K1.1624.32 million shs121.84 million shs
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
$0.00
$0.07
▼
$6.56
$1.04M1.36315,915 shs220 shs
7 Energy Stocks to Buy and Hold Forever Cover

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
+13.64%-2.71%+11.00%+53.33%+61.97%
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
0.00%-8.05%-95.90%-99.20%-99.72%
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
0.00%0.00%0.00%0.00%+150.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
0.00
N/AN/AN/A
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
0.00
N/AN/AN/A
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
2.29
Hold$11.5071,775.00% Upside
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest KPTI, ASLN, HEPA, and NMTR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/2/2026
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
DowngradeBuy ➝ Neutral
9/24/2026
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
DowngradeSell (D-) ➝ Sell (E+)
9/10/2026
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
UpgradeSell (E+) ➝ Sell (D-)
8/27/2026
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
DowngradeSell (D-) ➝ Sell (E+)
(Data available from 11/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
$12M0.10N/AN/A($6.50) per share-0.09
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
N/AN/AN/AN/A$1.29 per shareN/A
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
$146.07M0.00N/AN/A($16.00) per share0.00
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
N/AN/AN/AN/A$0.19 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
-$44.22M-$21.92N/AN/AN/AN/A-8,454.87%-121.60%N/A
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
-$48.93M-$72.15N/AN/AN/AN/A-812.56%-207.31%N/A
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
-$196.04M-$13.09N/AN/AN/A-153.28%N/A-145.18%N/A
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
-$43.77M-$3.46N/AN/AN/AN/A-584.97%-159.45%N/A

Latest KPTI, ASLN, HEPA, and NMTR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/16/2026Q3 2026
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
-$200.00-$0.06+$199.94N/AN/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
N/AN/AN/AN/AN/A
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
N/AN/AN/AN/AN/A
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
N/AN/AN/AN/AN/A
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
N/A
1.05
1.05
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
N/A
1.30
1.30
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
N/A
0.79
0.76
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
N/A
0.59
0.59

Institutional Ownership

CompanyInstitutional Ownership
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
58.82%
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
17.24%
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
66.44%
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
22.34%
CompanyEmployeesShares OutstandingFree FloatOptionable
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
302.04 million1.95 millionNo Data
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
2011.44 million6.63 millionNo Data
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
38022.68 million22.30 millionOptionable
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
2014.34 million13.99 millionNo Data

Recent News About These Companies

What is a prepayment meter?
Deal reached to sell some assets of bankrupt Raleigh firm
9 Meters Biopharma, Inc. (NMTRQ)
9 Meters Biopharma Inc (NMTRQ)
Vintage Meters Reborn As Steam Punk Clock
9 Meters Biopharma (OTC: NMTR.Q)
Why Are 9 Meters Biopharma Shares Nosediving Today?
Temperato resigns as CEO of Raleigh drugmaker
9 Meters Biopharma (NASDAQ: NMTR)
NMTR - 9 Meters Biopharma, Inc.

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASLAN Pharmaceuticals stock logo

ASLAN Pharmaceuticals NASDAQ:ASLN

$0.60 0.00 (0.00%)
As of 11/6/2026

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises eblasakimab (ASLAN004), a monoclonal antibody that targets the IL-13 receptor a1 subunit which is under Phase 2 developed for the treatment of atopic dermatitis and other immunology indications; and farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase currently under Phase 2 clinical trials for the treatment of autoimmune diseases. It has research collaboration agreement with Zenyaku Kogyo Co., Ltd. for the development and commercialization of eblasakimab in atopic dermatitis and all other indications in Japan. The company was founded in 2010 and is headquartered in Singapore.

Hepion Pharmaceuticals stock logo

Hepion Pharmaceuticals NASDAQ:HEPA

$0.12 +0.01 (+13.64%)
As of 11/17/2026 02:29 PM Eastern

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.

Karyopharm Therapeutics stock logo

Karyopharm Therapeutics NASDAQ:KPTI

$0.02 0.00 (-8.05%)
Closing price 11/10/2026
Extended Trading
$0.02 0.00 (0.00%)
As of 11/10/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

9 Meters Biopharma stock logo

9 Meters Biopharma NASDAQ:NMTR

9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. Its lead product candidate is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome. The company is developing NM-136, a humanized monoclonal antibody for the treatment of obesity and obesity-related disorders; NM-102, a small molecule peptide to prevent antigens from trafficking into systemic circulation; and NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease. Its partnered product is Larazotide, an 8-amino acid peptide, which is in Phase 2 clinical trial for treatment of multi-system inflammatory syndrome. The company has licensing agreements with Amunix, MHS Care Innovation LLC, Alba Therapeutics Corporation, and EBRIS. 9 Meters Biopharma, Inc. is headquartered in Raleigh, North Carolina. On July 17, 2023, 9 Meters Biopharma, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Eastern District of North Carolina.